Ascent Scientific launches first commercial source of TMCB – a novel selective CK2 inhibitor
September 01, 2009 (PRLEAP.COM) Health NewsAscent Scientific (www.ascentscientific.com) announced the availability of the first commercial source of TMCB - a new kinase inhibitor that is selective for CK2. It is more selective than the prototypic CK2 inhibitor DMAT over a range of other kinases.
Steve Roome PhD, Commercial Director commented, "Ascent Scientific is proud to be the first life science supplier to make this exciting kinase inhibitor commercially available to the scientific community. Up until now, many researchers have used DMAT to inhibit CK2. However, unlike DMAT, TMCB displays selectivity over PIM1, HIPK2 and DYRK1a and displays a more favourable selectivity profile over a range of other kinases."
Iain Sandison, Science Director added, "TMCB is available at very high purity (at least 99%). And of course, in keeping with our philosophy, we have introduced it at an affordable price!"
Contact: Steve Roome, Commercial Director +44 (0)117 982 99 88 firstname.lastname@example.org
About Ascent Scientific
Ascent Scientific offers a range of high quality receptor ligands and synthetic chemistry services at prices so low that as many researchers as possible will be able to afford them.
The Low-Cost Ligand range includes receptor ligands and signalling tools in research areas such as glutamate, GABA, ion channels, cannabinoids, opioids, 5-HT and more.
The Low-Cost Chemistry Service provides cost-effective custom synthesis of organic molecules, fluorescent labels, standards & references, stable isotope labels, receptor ligands and more.
Ascent Scientific operates out of UK headquarters close to Bristol, and a US Sales & Distribution office in New Jersey.
To request a new catalogue, visit our website www.ascentscientific.com, or contact customer service at email@example.com.